Abstract: Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, or thrombocytopenia).

Abstract: Methods for ameliorating neurodegenerative disorders and methods for ameliorating inflammatory disorders comprising administering to said subject an effective amount of a polypeptide comprising, in order from N-terminus to C-terminus, R-X1-X2-X3-X4-X5-R? wherein: R is optionally 1-5 additional ?-amino acids of either L-configuration or D configuration; X1 is any amino acid of either L-configuration or D-configuration; X2 is any amino acid of either L-configuration or D-configuration; X3 is Asp or Glu of either L-configuration or D-configuration; X4 is any amino acid of either L-configuration or D-configuration; X5 is any amino acid of either L-configuration or D-configuration; and R? is optionally 1-5 additional ?-amino acids of either L-configuration or D-configuration, with the proviso that at least three of X1, X2, X3, X4, and X5 are of the D-configuration, wherein the N-terminus is optionally modified by acetylation, and wherein the C-terminus is optionally modified by amidation and/or methylation.

Abstract: A compound composition for improving bone health and preparation and application thereof are provided. The compound composition is prepared by combining a traditional Chinese medicine extract with chicken cartilage collagen, magnesium, vitamin K2 and vitamin D3. The compound composition overcomes the food safety risk of the existing osteoporosis preventive drugs by adding the traditional Chinese medicine extract for improving osteoporosis and promoting bone health. And the compound composition disclosed can be used as a dietary supplement or health food raw material for preventing or treating osteoporosis. Therefore, the compound composition disclosed is suitable for promotion and application.

Abstract: Disclosed is a wound treatment that includes collagen and a gelatin-reducing agent. Also disclosed is a wound dressing including a substrate, collagen, and a gelatin-reducing agent. The collagen and gelatin-reducing agent may be present in any suitable a weight ratio relative to one another, such as a weight ratio of about 0.25:1 to about 4:1 with respect to one another. Also disclosed is a method for promoting wound healing including administering collagen and a gelatin-reducing agent to a wound in need of treatment.

Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.

Abstract: Method for suppressing bone cancer-induced allodynia in a patient, the method comprising administration of a therapeutically effective amount of a non-cytotoxic protease to a patient suffering from bone cancer.

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.

Abstract: The present invention provides compositions for treating or preventing cancer and methods of using and making the compositions. The compositions comprise herpes simplex viruses comprising recombinant herpes simplex virus genomes. Further provided are recombinant herpes simplex virus genomes, viruses comprising the recombinant herpes simplex virus genomes, and cancer vaccines and other compositions comprising the viruses.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.

Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.

Abstract: Bacterial pathogens have evolved means to succeed as pathogens by infecting without recognition by receptors triggering innate immunity, by suppressing induction of immunity and by inducing immune responses to antigens that confer no protectives immunity. Embodiments described herein circumvent these abilities in Salmonella so as to provide a vector system that induces maximal protective immune responses. Another major problem in using live attenuated bacterial vaccine vectors is the accumulation of attenuating mutations that confer a virulence and safety but which decrease the ability of the vaccine to invade cells in the MALT to colonize and persist in internal effector lymphoid tissues.

Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.

Abstract: Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject.

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: Provided are human polyclonal immunoglobulin products for use in treating or preventing coronavirus disease. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.

Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.

Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

Abstract: Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

Abstract: The present invention pertains to affinity chromatography isolation and purification of extracellular vesicles (EVs). The EVs of the present invention are engineered to enable highly specific binding to e.g. chromatography matrices, which is highly useful for affinity-based isolation and purification of EVs from complex biological fluids such as cell culture medium or biological fluids.

Abstract: A method for ablating cancerous tissue in a subject, the method comprising incorporating a sound excitable compound into said cancerous tissue followed by exposure of said cancerous tissue to low-intensity ultrasound having an intensity of no more than 5 W/cm2, said sound excitable compound having the structure Formula (1) wherein: X1, X2, X3, and X4 are each independently selected from iodine and bromine atoms; X5, X6, X7, and X8 are each independently selected from hydrogen atom, chlorine, bromine, and iodine atoms; Y1 is an —O—, —NR?—, or —CR?2— linker, wherein R? is independently selected from hydrogen atom and methyl; Z is a hydrocarbon linking group containing 1-12 carbon atoms; R1 is selected from hydrogen atom, methyl, —OH, and —OR groups, wherein R is an alkyl group containing one to three carbon atoms; and wherein said Formula (1) includes pharmaceutically acceptable salts and solvates of the compounds embraced by Formula (1).

Abstract: The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.

Abstract: Disclosed is a process for preparation of heterogeneous monodisperse mixtures of protein conjugates with a defined degree of conjugation (1-8) obtained by using a tri-functional reagent allowing affinity concentration followed by subsequent simultaneous release-functionalization.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: A cell-penetrating peptide (CPP) comprising a plurality of mono(amino acid)s, oligo(amino acid)s, or poly(amino acid)s where a plurality of the amino acids comprise a positively charged guanylurea unit with a small molecule fragment and each of the mono(amino acid)s, oligo(amino acid)s, or poly(amino acid)s comprising a drug attached through a linker. The CPP can be used for treating cancers.

Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.

Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: This invention provides a DNA comprising any of the following (a) to (c): (a) a DNA comprising any of the base sequences of positions 16 to 831 of SEQ ID NO: 1, positions 16 to 822 of SEQ ID NO: 3, positions 16 to 825 of SEQ ID NO: 5, positions 16 to 819 of SEQ ID NO: 7, positions 16 to 834 of SEQ ID NO: 9, and positions 16 to 828 of SEQ ID NO: 11; (b) a DNA encoding a polypeptide comprising any of the amino acid sequences of positions 1 to 272 of SEQ ID NO: 2, positions 1 to 269 of SEQ ID NO: 4, positions 1 to 270 of SEQ ID NO: 6, positions 1 to 268 of SEQ ID NO: 8, positions 1 to 273 of SEQ ID NO: 10, and positions 1 to 271 of SEQ ID NO: 12; and (c) a complementary strand of the DNA (a) or (b).

Abstract: Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting agents.

Abstract: The present invention relates to restorative purpose acrylic dental composite filling material which are curable by light and are polymerizable, and which contains only ?-tricalcium phosphate (?-TCP), nanocrystalline cellulose (NCC), hydroxy apatite particles/fibers/whiskers, AI—Sr—OF and AI—Sr—Si—OF and/or mixtures thereof as supportive phase system for conferring regenerative and antibacterial properties to composite filling materials, and relates to production method of said dental composite filling material.

Abstract: A wet wipe with a substrate having cellulosic fibers and a lotion is provided. The lotion may have between about 96.0% and about 99.5%, by weight of the lotion, of water. The lotion may have a preservative system having benzoic acid and/or a salt thereof, succinic acid and/or a salt thereof, and phytic acid and/or a salt thereof. The lotion may also have a surfactant, pH buffering system, and a pH of about 3.5 to about 5.

Abstract: A composition for application to a surface of skin includes from 0.1% to 1% by weight of at least one antimicrobial agent for disrupting a microbial cell, from 0.025% to 0.2% by weight of sodium gluconate as a micro-preservative potentiator also for disrupting a microbial cell, from 0.5% to 8% by weight of ethylhexyl isononanoate as an emollient for moisturizing a surface of skin, and from 0.005% to 0.04% by weight of a hyaluronic complex for hydrating the surface of skin. The hyaluronic complex includes a combination of hyaluronic acid, a salt derivative of hyaluronic acid, phenoxyethanol and water.

Abstract: This invention relates to syndet-based compositions having pH of 4.5 to 5.5 wherein use of caprylic acid has been unexpectedly found to enhance bacterial kill.

Abstract: A method for removing keratotic plugs capable of sufficiently exhibiting an excellent keratotic plug-removing effect without a burden, such as pam and of irritation, on the skin. The method comprises applying a composition comprising (X) one or more selected from (X1) 2-amino-2-hydroxymethyl-1,3-propanediol, (X2) 2-amino-2-methyl-1-propanol, and (X3) 2-amino-2-methyl-1,3-propanediol and a nonionic surfactant to the skin.

Abstract: Personal care compositions and methods for treating or preventing lipid peroxidation of skin with the same are disclosed. The personal care composition may include a carrier and a surfactant system present in an effective amount to treat or prevent lipid peroxidation of skin. The surfactant system may include at least one amphoteric surfactant and at least one anionic surfactant. The method may include contacting the personal care composition with the skin and exposing the skin to pollution. Methods for formulation a personal care composition for treating or preventing lipid peroxidation of skin are also disclosed. The method may include determining an oxidation protection factor (OPF) of one or more components, using the OPF to select at least one component of the one or more components, and combining the at least one component of the one or more components with a carrier to form the personal care composition.

Abstract: A personal care composition is provided, comprising: a vehicle; a cosmetically acceptable oil; and a cationic polymer comprising structural units of acrylamide monomer; structural units of N,N-dimethyl acrylamide monomer; and structural units of monoethylenically unsaturated monocationic monomer; wherein the cationic polymer comprises <10 mol % structural units of multiethylenically unsaturated cationic monomer; wherein the cationic polymer comprises <30 wt % structural units of ester containing monomers; wherein the cationic polymer comprises <1 mol % structural units of ethylenically unsaturated monomers containing a moiety selected from the group consisting of epoxy, anhydride, imide, lactone, carboxylic acid, sulfonic acid and isocyanate; wherein the cationic polymer comprises <0.1 mol % structural units of a reactive siloxane; and wherein the personal care composition comprises <0.05 wt % water soluble, organic, ampholytic polymer conditioning agent.

Abstract: A composition for conditioning keratin fibers, comprising: (a) at least one (C10-C30)alkylamido(C1-C8)alkyl(di)(C1-C6)alkylamine and their cosmetic salts and their solvates such as hydrates; (b) at least one dicarboxylic acid containing at least one hydroxyl group, preferably two hydroxyl groups, the said dicarboxylic acid not bearing a cyclic group; (c) at least one oil from eater of C6-C20 fatty acid and C6-C20 fatty alcohol; The composition provides to the keratin fibers, in particular the hair, an improved disentangling, and smoothness sensory.

Abstract: A solid cleansing product including at least a first surfactant and a second surfactant present in a combined surfactant weight amount, both of the first and second surfactants being free of sulfate-containing materials; at least a first buffering agent and a second buffering agent a present in a combined buffering agent weight amount; where the combined buffering agent weight amount is at least double the combined surfactant weight amount.

Abstract: A composition for enhancing protein strength according to the present invention contains an aminosilane compound capable of covalent binding with a protein of hair, scalp, skin, nails, leather, or textile, so that the protein and the amino silane compound form a covalent bond, and thus the composition can improve the protein strength enhancement effect and maximize the semi-permanent protein strength enhancement effect.

Abstract: The instant disclosure relates to hair treatment compositions that include a unique combination of components that function to impart desirable cosmetic properties to the hair. The hair treatment compositions typically include: at least 0.5 wt. % of at least one non-polymeric mono, di, or tricarboxylic acid, and/or a salt thereof; one or more amines selected from the group consisting of diamines, polyamines, alkylamines, alkanolamines, and a mixture thereof; one or more fructan polysaccharides; one or more prosolvents; and water.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, and more preferably a skin cosmetic composition, comprising: (a) at least one complex, comprising at least one cationic polymer and at least one anionic polymer, at least one cationic polymer and at least one amphoteric polymer, at least one anionic polymer and at least one amphoteric polymer, or at least one amphoteric polymer, and at least one non-polymeric acid having two or more pKa values or salt(s) thereof or at least one non-polymeric base having two or more pKb values or salt(s) thereof; (b) at least one oil; and (c) water, wherein the cationic polymer comprises at least one cationic cellulose polymer with at least one fatty chain comprising at least 10 carbon atoms, and if the (a) complex comprises at least one anionic polymer and at least one amphoteric polymer, or at least one amphoteric polymer, the (a) complex further comprises at least one cationic cellulose polymer with at least one fatty chain comprising at leas

Abstract: The invention relates to three-part makeup remover compositions comprising (a) a water part; (b) an oil part; and (c) a silicone-in-water emulsion part.

Abstract: Disclosed is a callus lysate containing a callus metabolite without a loss of callus metabolite and its preparation method, a capsule containing a callus lysate prepared through encapsulation by coating the callus lysate with a natural polymer material and its preparation method, and composition for external skin application and a cosmetic composition that includes the callus lysate or the capsule containing the callus lysate as an active ingredient, wherein the callus lysate of the present invention contains a large amount of a callus metabolite without a loss of callus metabolite and thus allows penetration or absorption of callus metabolite directly into the skin, thereby providing effects of the callus metabolite to prevent and improve various skin diseases and symptoms.

Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

Abstract: There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.

Abstract: Aqueous nanosuspensions of cannabidiol (CBD) having improved stability, shelf life, and/or CBD content are provided, as are methods of making such nanosuspensions. The nanosuspensions include ethyl maltol as an emulsifying agent and may be manufactured by either a melt emulsification process or a solvent evaporation process. The nanosuspensions may also have an improved taste and are thus suitable for use as, e.g., beverage additives.

Abstract: The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.